|
18 Sep 2021 |
Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial
|
|
18 Sep 2021 |
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
|
|
15 Sep 2021 |
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
|
|
15 Sep 2021 |
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
|
|
15 Sep 2021 |
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19
|
|
15 Sep 2021 |
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
|
|
15 Sep 2021 |
Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
|
|
15 Sep 2021 |
Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta
|
|
09 Sep 2021 |
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, including the Delta Variant
|
|
09 Sep 2021 |
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
|
|
04 Sep 2021 |
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
|
|
02 Sep 2021 |
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
|
|
02 Sep 2021 |
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
|
|
02 Sep 2021 |
Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate
|
|
01 Sep 2021 |
Entos Pharmaceuticals' COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South Africa
|
|
01 Sep 2021 |
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
|
|
31 Aug 2021 |
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
|
|
31 Aug 2021 |
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
|
|
31 Aug 2021 |
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
|
|
26 Aug 2021 |
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
|
|
26 Aug 2021 |
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
|
|
26 Aug 2021 |
Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
|
|
26 Aug 2021 |
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
|
|
24 Aug 2021 |
BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine
|
|
24 Aug 2021 |
Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer
|
